<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01315795</url>
  </required_header>
  <id_info>
    <org_study_id>2010-024604-10</org_study_id>
    <nct_id>NCT01315795</nct_id>
  </id_info>
  <brief_title>Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease</brief_title>
  <acronym>LOCKCYST</acronym>
  <official_title>An Open-label, Phase II Clinical Study to Evaluate the Efficacy and Safety of Lanreotide Autogel 90mg Every 4 Weeks in the Treatment of Symptomatic Polycystic Liver Disease, Including a Dose Escalation at Month 6 to Lanreotide Autogel 120mg for Non Responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, Phase II clinical study to evaluate the efficacy and safety of lanreotide
      autogel 90mg every 4 weeks in the treatment of symptomatic polycystic liver disease,
      including a dose escalation at month 6 to lanreotide autogel 120mg for non responders.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of total liver volume after 6 months of treatment measured by means of CT-scan.</measure>
    <time_frame>6 months</time_frame>
    <description>Reduction of total liver volume after 6 months measured by means of CT-scan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of total liver volume after 12 months of treatment by means of CT-scan</measure>
    <time_frame>12 months</time_frame>
    <description>Reduction of total liver volume after 12 months of treatment by means of CT-scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of total liver volume after 18 months of treatment by means of CT-scan</measure>
    <time_frame>18 months</time_frame>
    <description>Reduction of total liver volume after 18 months of treatment by means of CT-scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of total liver and kidney volumes and cyst volumes at baseline.</measure>
    <time_frame>Baseline</time_frame>
    <description>Reduction of total liver volume Reduction of liver cyst volume Additonal reduction of total liver volume in the non responder group. Additonal reduction of liver cyst volume in the non responder group.
% of patients with liver reduction &gt; 100 ml in the non responder group. Reduction of total kidney volume (ADPKD patients only) after 6 months, 1 year and 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of total liver and kidney volumes and cyst volumes after 6 months of treatment by means of CT scan</measure>
    <time_frame>6 months</time_frame>
    <description>Reduction of total liver volume Reduction of liver cyst volume Additonal reduction of total liver volume in the non responder group. Additonal reduction of liver cyst volume in the non responder group.
% of patients with liver reduction &gt; 100 ml in the non responder group. Reduction of total kidney volume (ADPKD patients only) after 6 months, 1 year and 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of total liver and kidney volume and cyst volume after 12 months of treatment by means of CT scan.</measure>
    <time_frame>12 months</time_frame>
    <description>Reduction of total liver volume Reduction of liver cyst volume Additonal reduction of total liver volume in the non responder group. Additonal reduction of liver cyst volume in the non responder group.
% of patients with liver reduction &gt; 100 ml in the non responder group. Reduction of total kidney volume (ADPKD patients only) after 6 months, 1 year and 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of total liver and kidney volumes and cyst volumes after 18 months of treatment by means of CT scan</measure>
    <time_frame>18 months</time_frame>
    <description>Reduction of total liver volume Reduction of liver cyst volume Additonal reduction of total liver volume in the non responder group. Additonal reduction of liver cyst volume in the non responder group.
% of patients with liver reduction &gt; 100 ml in the non responder group. Reduction of total kidney volume (ADPKD patients only) after 6 months, 1 year and 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life at baseline</measure>
    <time_frame>baseline</time_frame>
    <description>Assessment of quality of life at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life after 6 months of treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of quality of life after 6 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life after 12 months of treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Assessment of quality of life after 12 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life after 18 months of treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Assessment of quality of life after 18 months of treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Polycystic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Symptomatic polycystic liver disease (PCLD) patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Symptomatic polycystic liver disease (PCLD) patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanreotide Autogel 90 mg and 120 mg</intervention_name>
    <description>administration of lanreotide sc every 4 weeks (28 days)</description>
    <arm_group_label>Symptomatic polycystic liver disease (PCLD) patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver volume ≥ 4 liter

          -  ≥ 20 liver cysts

          -  Symptomatic patients defined as at least 2 out of 5 of the following symptoms related
             to mass effect irrespective of the intensity:

               -  Abdominal distention perceived as uncomfortable

               -  Frequent abdominal pain

               -  Early satiety

               -  Nausea (with the inclusion of dyspeptic complaints)

               -  Dyspnea

          -  Diagnosed with ADPKD or ADPLD

          -  Male and female patients of 18 years and older

          -  Written informed consent

        Exclusion Criteria:

          -  Creatinine clearance &lt; 20 ml/min

          -  Patient who underwent a kidney transplant and received variable doses of
             immunosuppressive therapy and/or present signs of rejection in the past year

          -  Hormonal replacement therapy

          -  Hormonal contraception

          -  Pregnant or lactating

          -  Presenting with an uncontrolled disease (other than ADPKD/ADPLD)

          -  Planned to undergo any surgery of the liver during study participation

          -  Planned to undergo any surgery of the KIDNEY during study participation (ADPKD
             patients only)

          -  Patients with known allergies to somatostatin or its analogues or any of its
             components

          -  Patients who received somatostatin analogues in the 6 months preceding study inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederik Nevens, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven, Gasthuisberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Leuven, Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <state>Provincie Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/19646443</url>
    <description>Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.</description>
  </link>
  <results_reference>
    <citation>van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, Drenth JP. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2009 Nov;137(5):1661-8.e1-2. doi: 10.1053/j.gastro.2009.07.052. Epub 2009 Jul 29.</citation>
    <PMID>19646443</PMID>
  </results_reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2011</study_first_submitted>
  <study_first_submitted_qc>March 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2011</study_first_posted>
  <last_update_submitted>July 7, 2014</last_update_submitted>
  <last_update_submitted_qc>July 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Dr Frederik Temmerman</investigator_full_name>
    <investigator_title>Professor Dr Frederik Nevens</investigator_title>
  </responsible_party>
  <keyword>polycystic liver disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Cysts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

